Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female subjects from 45 to 85 years of age~* Definite IPF within 3 years prior to screening~* Be able to walk at least 50 meters~Key Exclusion Criteria:~* Significant diseases other than IPF~* Obstructive lung disease~* Aortic aneurysm greater than or equal to 3.5 cm in diameter~* Treatment with immunosuppressive, cytotoxic, or antifibrotic drugs \< 28 days prior to randomization are not permitted.~  * N-acetylcysteine is permitted provided the individual has been on a stable dose for \> 4 weeks prior to screening~ * Concomitant use of pirfenidone or nintedanib must be in accordance with the approved prescribing instructions in the country where the site is located~* Individuals actively listed for lung transplant are excluded. However individuals at transplant centers with long waiting times (greater than 1 year) may be permitted to enter the study after discussion with Medical Monitor.~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Simtuzumab (Type: EXPERIMENTAL): Participants will receive simtuzumab for up to 254 weeks.
- Simtuzumab Placebo (Type: PLACEBO_COMPARATOR): Participants will receive simtuzumab placebo for up to 254 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).